Future clinical trials should examine the effects of repeated daily delivery of TENS, similar to the way in which TENS is used clinically on pain, fatigue, function, and quality of life in individuals with fibromyalgia.
Once deviations from random assignments occur, regardless of the reason, scientists running trials should examine how treatment contamination has affected their results.
Future trials should examine a range of short-term analgesia and longer outcomes like interference with daily living or absence from work or school.
The results of the BCG revaccination trial show that non-vaccine factors might undermine this assumption, and the authors conclude correctly that trials should examine the impact of vaccines on survival.
Seventh, most trials excluded patients with pain from some other disorders, such as rheumatoid arthritis, inflammatory arthritis or autoimmune disease, and future trials should examine the efficacy of medications in these patients.
Finally, large-scale randomized controlled trials should examine the potential for mediated relationships between effects of text4baby and other mHealth programs on health cognitions and subsequent behavior change over time.
We also suggest that researchers of ongoing trials should examine their data in relation to both histology (either nonsquamous or squamous) and early assessment of tumor response, as prespecified subgroup analyses.
Future trials should examine whether survival differs between a strategy to perform therapeutic LPs based on CSF opening pressures >250 mmH2O vs a strategy using a predefined schedule of lumbar punctures (eg, on days 1, 3, 7, and 14) for all patients.
The optimal treatment strategy in mRCC is likely to be defined in future randomized trials that should examine combination therapies of these active agents.
